[Guillain-Barré syndrome. What should be done, when the treatment appears to fail?].
Tellería-Díaz
A
A
MTI, Klinikum der Friedrich Schiller Universität Jena, Jena, Alemania. diaz@mti-n.uni-jena.de
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D020275:Guillain-Barre Syndrome / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D017211:Treatment Failure
D000276:Adjuvants, Immunologic; D016756:Immunoglobulins, Intravenous